SCHEMBL5831396

SCHEMBL5831396

O=[N+]([O-])c1ccc(Cl)c(-c2nsc(NS(=O)(=O)c3ccc(-c4ccccc4)cc3)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
POLB P06746 1/20 0.50
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
KDM1A O60341 5/20 0.48
USP36 Q9P275 1/20 0.46
MAOA P21397 1/20 0.45
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP2C8 P10632 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831119 0.84 KDM1A (0.54) MEN1KMT2AKDM1AUSP36MAOA
SCHEMBL7132055 0.84 KMT2A (0.43) MEN1KMT2APOLBCRHBPCRHR2
SCHEMBL5831383 0.83 MEN1 (0.46) MEN1KMT2APOLBCRHBPCRHR2
SCHEMBL5830398 0.83 MEN1 (0.47) MEN1KMT2APOLBCRHBPCRHR2
SCHEMBL5402006 0.83 MEN1 (0.63) MEN1KMT2APOLBKDM1AUSP36
SCHEMBL2762577 0.82 MEN1 (0.70) MEN1KMT2APOLBKDM1AMAOA
SCHEMBL5831323 0.82 MEN1 (0.57) MEN1KMT2APOLBCRHBPCRHR2
SCHEMBL5831701 0.80 FSCN1 (0.44) MEN1KMT2APOLBKDM1ALMNA
SCHEMBL6930430 0.80 MAPT (0.41) MEN1KMT2APOLBKDM1AMAOA
SCHEMBL5831040 0.79 KMT2A (0.43) MEN1KMT2AKDM1AMAOAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 MEN1 903/4885KMT2A 2980/4885POLB 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.